220 related articles for article (PubMed ID: 32529327)
21. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2.
Dudakovic A; Samsonraj RM; Paradise CR; Galeano-Garces C; Mol MO; Galeano-Garces D; Zan P; Galvan ML; Hevesi M; Pichurin O; Thaler R; Begun DL; Kloen P; Karperien M; Larson AN; Westendorf JJ; Cool SM; van Wijnen AJ
J Biol Chem; 2020 Jun; 295(23):7877-7893. PubMed ID: 32332097
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-630 Suppresses Epithelial-to-Mesenchymal Transition by Regulating FoxM1 in Gastric Cancer Cells.
Feng J; Wang X; Zhu W; Chen S; Feng C
Biochemistry (Mosc); 2017 Jun; 82(6):707-714. PubMed ID: 28601080
[TBL] [Abstract][Full Text] [Related]
25. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
26. PARI functions as a new transcriptional target of FOXM1 involved in gastric cancer development.
Zhang Y; Ye X; Chen L; Wu Q; Gao Y; Li Y
Int J Biol Sci; 2018; 14(5):531-541. PubMed ID: 29805304
[TBL] [Abstract][Full Text] [Related]
27. Expression and mechanism of exosome-mediated A FOXM1 related long noncoding RNA in gastric cancer.
Zhang Y; Chen L; Ye X; Wu Z; Zhang Z; Sun B; Fu H; Fu C; Liang X; Jiang H
J Nanobiotechnology; 2021 May; 19(1):133. PubMed ID: 33971889
[TBL] [Abstract][Full Text] [Related]
28. Diosgenin and GSK126 Produce Synergistic Effects on Epithelial-Mesenchymal Transition in Gastric Cancer Cells by Mediating EZH2 via the Rho/ROCK Signaling Pathway.
Liu S; Rong G; Li X; Geng L; Zeng Z; Jiang D; Yang J; Wei Y
Onco Targets Ther; 2020; 13():5057-5067. PubMed ID: 32606728
[TBL] [Abstract][Full Text] [Related]
29. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
30. EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
Barazeghi E; Hellman P; Norlén O; Westin G; Stålberg P
Sci Rep; 2021 Nov; 11(1):22733. PubMed ID: 34815475
[TBL] [Abstract][Full Text] [Related]
31. Dextran Sulfate Inhibits Cell Proliferation and Induces Apoptosis by Regulating EZH2 in Gastric Carcinoma.
Huang Y; Wang W; Xu YY; Guo J; Jiao L; Wang H; Li M; Yang Q
Curr Cancer Drug Targets; 2021; 21(11):953-964. PubMed ID: 34551698
[TBL] [Abstract][Full Text] [Related]
32. EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis.
Ihira K; Dong P; Xiong Y; Watari H; Konno Y; Hanley SJ; Noguchi M; Hirata N; Suizu F; Yamada T; Kudo M; Sakuragi N
Oncotarget; 2017 Feb; 8(8):13509-13520. PubMed ID: 28088786
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
34. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
35. Estrogen-related receptor-γ regulates estrogen receptor-α responsiveness in uterine endometrial cancer.
Yamamoto T; Mori T; Sawada M; Kuroboshi H; Tatsumi H; Yoshioka T; Matsushima H; Iwasaku K; Kitawaki J
Int J Gynecol Cancer; 2012 Nov; 22(9):1509-16. PubMed ID: 23051957
[TBL] [Abstract][Full Text] [Related]
36. Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.
Francica P; Nisa L; Aebersold DM; Langer R; Bladt F; Blaukat A; Stroka D; Martínez MR; Zimmer Y; Medová M
Clin Cancer Res; 2016 Nov; 22(21):5322-5336. PubMed ID: 27185371
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of the Akt/FOXM1 Signaling Pathway by Panobinostat Suppresses the Proliferation and Metastasis of Gastric Cancer Cells.
Lee NR; Kim DY; Jin H; Meng R; Chae OH; Kim SH; Park BH; Kim SM
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073071
[TBL] [Abstract][Full Text] [Related]
38. METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy.
Xin L; Zhou Q; Yuan YW; Zhou LQ; Liu L; Li SH; Liu C
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2507-2517. PubMed ID: 31485766
[TBL] [Abstract][Full Text] [Related]
39. Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.
Shankar E; Franco D; Iqbal O; Moreton S; Kanwal R; Gupta S
Toxicol Appl Pharmacol; 2020 Oct; 404():115200. PubMed ID: 32805266
[TBL] [Abstract][Full Text] [Related]
40. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
Otsuka Y; Nishikori M; Arima H; Izumi K; Kitawaki T; Hishizawa M; Takaori-Kondo A
Mol Immunol; 2020 Mar; 119():35-45. PubMed ID: 31962268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
